Experimental women's cancer drug boosts survival rates in notable study
A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...
Corcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success
Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast
Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in ...
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...
Corcept Therapeutics announces ROSELLA trial meets primary endpoint
Corcept Therapeutics (CORT) announced that Rosella, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with ...
Fierce Biotech2d
Corcept's investigational oral therapy cuts ovarian cancer progression by 30%, teeing up FDA filing
Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...
Zacks.com on MSN1d
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal
The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...
CURE2d
Relacorilant Plus Chemo Meets Primary Goal in Ovarian Cancer Trial
The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...
MPR2d
Relacorilant Looks Promising for Platinum-Resistant Ovarian Cancer
The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.
Nasdaq2d
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
In ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 30 percent reduction in risk of disease progression compared to patients treated with nab ...